Search Results

You are looking at 261 - 270 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

HSR24-154: Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy—An Analysis of the ADOReg German Skin Cancer Registry

Ruixuan Jiang, Michael Weichenthal, Cesar I. Fernandez-Lazaro, Anja Rudolph, Clemens Krepler, Peter Mohr, and on behalf of the ADOReg investigators

Background: Brain metastases are associated with poor clinical outcomes in advanced/metastatic melanoma, with median overall survival (OS), historically, of 3–6 months. The ADOReg German skin cancer registry provides an opportunity to evaluate

Full access

HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data

Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Eric Padron, and David Sallman

limited efficacy and durability. In this study, the association between RBC-TD and outcomes was assessed. Methods: A large US commercial health claims database (including ∼17–19M annual covered lives) identified LR-MDS pts using ICD-10 codes (D46.0, D46

Full access

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar

associated with higher molecular response rates to imatinib. 17 – 20 While some studies have demonstrated a trend toward better survival outcomes with e14a2 transcript, 18 , 19 in other studies the type of transcript did not have any significant impact on

Full access

HSR24-138: Real-World Treatment (tx) Patterns and Outcomes for First-Line (1L) Novel Hormonal Agent (NHA) Naïve Metastatic Castration Resistant Prostate Cancer (mCRPC) Including in Black and/or African American (BAA) Patients (Pts)

Emily Nash Smyth, Samuel Whipple, Mark Guinter, Nadine Haddad, Wenxian Piao, Zhanglin Cui, and Arjun Balar

are NHA-naïve is unknown, and data describing tx patterns and clinical outcomes are limited. We evaluated tx patterns and outcomes for 1L NHA-naïve mCRPC, including BAA given the differential impact of metastatic prostate cancer in this important pt

Full access

CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Lilian Hanna, Gordon Taylor Moffat, Wilma Hopman, Pierre-Olivier Gaudreau, and Andrea S. Fung

Background : The addition of durvalumab following chemoradiation in unresectable Stage III NSCLC has led to improved cancer outcomes. The schedule of administration has largely been determined by pharmacokinetic studies with a paucity of data

Full access

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

patients from the first evidence of PCa (surgery date, radiation therapy date, ADT initiation, or diagnosis) beginning January 1996 through the end of follow-up. Outcomes Five types of CVD events (incident or fatal) following GnRH agonists or

Full access

Factors Affecting Genetic Consultation in Adolescent and Young Adult Patients With Sarcoma

Grace E. McKay, Anna L. Zakas, Fauzia Osman, and Amanda Parkes

Primary Outcomes Of the 87 AYA patients with sarcoma identified in our study, only 22% (n=19) had documentation of a discussion about genetics with an oncology provider. There was no statistically significant difference in genetic discussion

Full access

BPI24-019: Estimation of Impact of Care Gap on Patient Outcome and Health Care Cost Burden Using Real World Data in Early-Stage NSCLC—An Empirical Study for Delay in Surgery

Atharv Sharma, Manu Prasad, Tianyuan Hu, Arunav Saikia, Prabhakar Gaur, Venkata Sai Sumanth Pulluri, and Stuti Jha

average of $4,806.84±$1,264.81 higher total healthcare resource costs ( P <0.001). Conclusion: Delay in surgery did not significantly impact eNSCLC patient outcomes, but substantially affected healthcare resource utilization. Similar results were

Full access

HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy

Jerome H Goldschmidt, Anupama Vasudevan, Michelle Silver, Jackie Kwong, and Elizabeth Marrett

1. Clinical Outcomes by Subsequent Treatment *Other sTx group not shown due to small sample size

Full access

HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

Weijia Wang, Edward Li, Kim Campbell, and Ali McBride

Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer